Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis
2011

Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis

Sample size: 39597 publication 10 minutes Evidence: moderate

Author Information

Author(s): David S. Wald, Joan K. Morris, Nicholas J. Wald

Primary Institution: Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine, Queen Mary University of London

Hypothesis

Does raised serum homocysteine cause ischaemic heart disease?

Conclusion

The discordant results from MTHFR studies and randomised trials suggest that aspirin may reduce or negate the anti-platelet effect of lowering homocysteine.

Supporting Evidence

  • Meta-analysis of MTHFR studies showed a statistically significant increased risk of ischaemic heart disease in TT compared with CC homozygotes.
  • Meta-analysis of randomised trials showed no significant reduction in IHD risk from folic acid.
  • There was a statistically significant difference in risk reduction between trials with low and high prevalence of antiplatelet therapy.

Takeaway

This study looked at how a substance called homocysteine in the blood might cause heart problems, and found that taking aspirin could change the results.

Methodology

Meta-analyses of 75 studies on MTHFR gene mutations and 14 randomised trials on homocysteine lowering.

Potential Biases

Potential publication bias may influence the results.

Limitations

The analysis could only be performed on 10 of the 14 trials, which may introduce bias.

Participant Demographics

Participants included individuals with and without ischaemic heart disease, with a total of 39,597 in randomised trials.

Statistical Information

P-Value

0.006

Confidence Interval

1.04 to 1.29

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016473

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication